HSPA1A and cancer: Altogether, the combination therapies targeting both Hsp70 and autophagy may offer a promising strategy to diminish therapeutic resistance in several refractory cancers and, furthermore, may enable a decrease in the dose of first-line chemotherapeutic drugs, potentially reducing therapeutic cytotoxicity and achieving better clinical responses in lung and other cancers.